Lewy Body Disease Pipeline Assessment, 2024 Updates | In-Depth Insights Into The Clinical Trials, Emerging Drugs, Latest Approvals, Treatment Outlook, Companies | Annovis Bio, Cervomed, Vaxxinity

(MENAFN- GetNews) disease Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest Approvals, treatment Outlook, Companies | Annovis Bio,
" Lewy="" Body="" Disease="" Pipeline="" Insights="" 2024"As="" per="" DelveInsight's="" assessment,="" globally,="" about="" 15+="" key="" pharma="" and="" biotech="" companies="" are="" working="" on="" 15+="" pipeline="" drugs="" in="" the="" Lewy="" Body="" Disease="" therapeutics="" landscape="" based="" on="" different="" Routes="" of="" Administration="" (ROA),="" Mechanism="" of="" Action="" (MOA),="" and="" molecule="" types.="" Several="" of="" the="" therapies="" are="" in="" the="" advanced="" stages="" of="" clinical="" development="" and="" are="" expected="" to="" launch="" in="" the="" coming="" />

“ Lewy Body Disease Pipeline Insight, 2024 ” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Lewy Body Disease Market.

The Lewy Body Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Lewy Body Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the emerging therapies for the
  treatment of Lewy Body Disease
  and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the
  Lewy Body Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development –

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)
  

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Lewy Body Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Lewy Body Disease Therapeutic Segment @

Lewy Body Disease Therapeutics Landscape

There are approx. 15+ key companies are
developing therapies for Lewy Body Disease. Currently,
Eli Lilly and Company
is leading the therapeutics market with its Lewy Body Disease drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Lewy Body Disease Therapeutics Market Include:

• Eisai Inc.

• EIP Pharma

• KeifeRx

• Generian Pharmaceuticals, Inc.

• Aptinyx

• Eli Lilly and Company

• Sun Pharma Advanced Research Company

• CuraSen Therapeutics

• NeuroActiva

• Neurimmune Therapeutics

• Voyager Therapeutics

• Yumanity Therapeutics

• Immungenetics

• ProMIS Neurosciences

• NLS Pharmaceutics Ltd

• Inhibikase Therapeutics

And many others

Lewy Body Disease Drugs Covered in the Report Include:

• Irsenontrine (E 2027): Eisai Inc

• Neflamapimod: EIP Pharma

• Mevidalen: Eli Lilly and Company

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Contents

1. Report Introduction

2. Executive Summary

3. Lewy Body Disease Current Treatment Patterns

4. Lewy Body Disease – DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Lewy Body Disease Late Stage Products (Phase-III)

7. Lewy Body Disease Mid-Stage Products (Phase-II)

8. Lewy Body Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Lewy Body Disease Discontinued Products

13. Lewy Body Disease Product Profiles

14. Key Companies in the Lewy Body Disease Market

15. Key Products in the Lewy Body Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Lewy Body Disease Unmet Needs

18. Lewy Body Disease Future Perspectives

19. Lewy Body Disease Analyst Review

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

MENAFN22052024003238003268ID1108247246